DE69804624T2 - Selbstemulgierende formulierung enthaltend lipophile verbindungen - Google Patents

Selbstemulgierende formulierung enthaltend lipophile verbindungen

Info

Publication number
DE69804624T2
DE69804624T2 DE69804624T DE69804624T DE69804624T2 DE 69804624 T2 DE69804624 T2 DE 69804624T2 DE 69804624 T DE69804624 T DE 69804624T DE 69804624 T DE69804624 T DE 69804624T DE 69804624 T2 DE69804624 T2 DE 69804624T2
Authority
DE
Germany
Prior art keywords
self
diglyceride
monoglyceride
formulation containing
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69804624T
Other languages
English (en)
Other versions
DE69804624D1 (de
Inventor
Walter Morozowich
Ping Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE69804624D1 publication Critical patent/DE69804624D1/de
Application granted granted Critical
Publication of DE69804624T2 publication Critical patent/DE69804624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69804624T 1997-07-29 1998-07-27 Selbstemulgierende formulierung enthaltend lipophile verbindungen Expired - Lifetime DE69804624T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5407897P 1997-07-29 1997-07-29
PCT/US1998/014816 WO1999006043A1 (en) 1997-07-29 1998-07-27 Self-emulsifying formulation for lipophilic compounds

Publications (2)

Publication Number Publication Date
DE69804624D1 DE69804624D1 (de) 2002-05-08
DE69804624T2 true DE69804624T2 (de) 2002-09-19

Family

ID=21988649

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69804624T Expired - Lifetime DE69804624T2 (de) 1997-07-29 1998-07-27 Selbstemulgierende formulierung enthaltend lipophile verbindungen

Country Status (23)

Country Link
US (2) US6531139B1 (de)
EP (1) EP0999838B1 (de)
JP (1) JP5005847B2 (de)
KR (1) KR100509130B1 (de)
CN (1) CN1113650C (de)
AT (1) ATE215370T1 (de)
AU (1) AU728695B2 (de)
BR (1) BR9810866B1 (de)
CA (1) CA2294032A1 (de)
DE (1) DE69804624T2 (de)
DK (1) DK0999838T3 (de)
ES (1) ES2174462T3 (de)
FI (1) FI20000171A (de)
HK (1) HK1028877A1 (de)
HU (1) HU225160B1 (de)
NO (1) NO323773B1 (de)
NZ (1) NZ502567A (de)
PL (1) PL192080B1 (de)
PT (1) PT999838E (de)
RU (1) RU2203648C2 (de)
SI (1) SI0999838T1 (de)
SK (1) SK284579B6 (de)
WO (1) WO1999006043A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
AU3883700A (en) * 1999-03-31 2000-10-16 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
AU3091802A (en) * 2000-10-31 2002-05-15 Boehringer Ingelheim Pharma Oral dosage self-emulsifying formulations of pyranone protease inhibitors
KR20020066778A (ko) * 2001-02-13 2002-08-21 한국과학기술연구원 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
US6680470B1 (en) * 2001-11-14 2004-01-20 Dicon Fiberoptics, Inc. Interleaver with thermal and chromatic dispersion compensation
AU2002351169B2 (en) * 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US7182950B2 (en) * 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
WO2007063384A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2008058234A2 (en) * 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
RU2487128C2 (ru) * 2007-03-09 2013-07-10 Новартис Аг Соли 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона
CA2687630A1 (en) * 2007-05-23 2008-11-27 Boehringer Ingelheim International Gmbh Self-emulsifying formulation of tipranavir for oral administration
HU227873B1 (hu) * 2007-06-18 2012-05-29 Biogreen As Növényicsíra-alapú emulziók, eljárás az elõállításukra és alkalmazásuk
US20080319048A1 (en) * 2007-06-22 2008-12-25 Scidose Llc Solubilized formulation of docetaxel without tween 80
WO2009111057A2 (en) 2008-03-07 2009-09-11 Scidose Llc Fulvestrant formulations
EP2257220B1 (de) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Fussbetätigte multifunktionssteuerung für bildgebungssystem
US20110275717A1 (en) * 2008-11-28 2011-11-10 Advance Holdings Limited Pharmaceutical formulation comprising diclofenac
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ME01718B (me) 2009-07-07 2014-09-20 Boehringer Ingelheim Int Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C
EP2488022B1 (de) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Zusammensetzungen
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
EA027666B1 (ru) 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
WO2012039768A2 (en) * 2010-09-24 2012-03-29 Texas Southern University Itraconazole formulations
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10711238B2 (en) 2012-10-02 2020-07-14 Repligen Corporation Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
JP6605047B2 (ja) 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド 疼痛治療のためのセレコキシブの経口用組成物
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3544614A4 (de) 2016-11-28 2020-08-05 Lipocine Inc. Orale testosteron-undecanoat-therapie
TWI676824B (zh) 2019-01-09 2019-11-11 友達光電股份有限公司 顯示裝置及顯示方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230702A (en) * 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
JPH0629180B2 (ja) * 1986-06-16 1994-04-20 エーザイ株式会社 吸収性の改良されたメナテトレノン含有組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
JP2632010B2 (ja) * 1988-01-29 1997-07-16 三共株式会社 シクロスポリン製剤
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
EP1142568A1 (de) * 1992-09-25 2001-10-10 Novartis AG Pharmazeutische Zusammensetzungen mit Cyclosporine
JPH08502490A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 組成物
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
CZ292192B6 (cs) 1995-06-06 2003-08-13 F. Hoffmann-La Roche Ag Jednotková dávka farmaceutického prostředku, který je inhibitorem proteinázy
DE19537012A1 (de) * 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen

Also Published As

Publication number Publication date
ATE215370T1 (de) 2002-04-15
NO20000465D0 (no) 2000-01-28
NZ502567A (en) 2002-03-28
JP5005847B2 (ja) 2012-08-22
BR9810866B1 (pt) 2010-07-13
KR20010022364A (ko) 2001-03-15
SK182000A3 (en) 2000-12-11
EP0999838A1 (de) 2000-05-17
SI0999838T1 (en) 2002-08-31
BR9810866A (pt) 2000-09-26
HUP0003292A1 (hu) 2002-01-28
ES2174462T3 (es) 2002-11-01
US6531139B1 (en) 2003-03-11
US6121313A (en) 2000-09-19
CN1113650C (zh) 2003-07-09
PL338334A1 (en) 2000-10-23
CN1261797A (zh) 2000-08-02
FI20000171A (fi) 2000-01-28
DE69804624D1 (de) 2002-05-08
HK1028877A1 (en) 2001-03-09
AU8573798A (en) 1999-02-22
JP2002510329A (ja) 2002-04-02
HU225160B1 (en) 2006-07-28
EP0999838B1 (de) 2002-04-03
NO20000465L (no) 2000-03-28
KR100509130B1 (ko) 2005-08-18
PT999838E (pt) 2002-07-31
AU728695B2 (en) 2001-01-18
HUP0003292A3 (en) 2002-02-28
DK0999838T3 (da) 2002-07-08
CA2294032A1 (en) 1999-02-11
WO1999006043A1 (en) 1999-02-11
NO323773B1 (no) 2007-07-02
PL192080B1 (pl) 2006-08-31
SK284579B6 (sk) 2005-07-01
RU2203648C2 (ru) 2003-05-10

Similar Documents

Publication Publication Date Title
DE69804624T2 (de) Selbstemulgierende formulierung enthaltend lipophile verbindungen
CA2294031A1 (en) SELF-EMULSIFYING FORMULATION FOR LIPOPHILIC COMPOUNDS
DE69808463D1 (de) Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
PT1011634E (pt) Preparacao de composicoes farmaceuticas
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
IT1281337B1 (it) Preparazione farmaceutica orale contenente ciclosporina come sostanza attiva ed un preconcentrato di emulsione multipla
HUP0500843A2 (hu) Fokozott biológiai hasznosulású, szájon át hatásos taxánszármazékokat tartalmazó gyógyszerkészítmények
ES2154661T3 (es) Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion.
ATE258427T1 (de) Pharmazeutische formulierungen enthaltend entzündungshemmende wirkstoffe und deren verwendung
JPS5668619A (en) Nifedipine-containing solid composition

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN COMPANY LLC (N.D.GES.D.STAA, US

8327 Change in the person/name/address of the patent owner

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, 55218, DE